 WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Cellular Biomedicine Group, Inc. CBMG or the Company NASDAQ: CBMG in connection with the proposed interested-party acquisition of the Company by a newly-formed entity consisting of CBMGs CEO Tony Liu, certain member of the Companys management, and a consortium of stockholders and equity investors the Affiliates. Under the terms of the acquisition agreement, CBMG shareholders will receive 19.75 in cash for each share they own. 